Aoxing Pharmaceutical Company Inc (AOXG) fair value: what the stock is really worth
As of Sep 22, 2026: fair value of Aoxing Pharmaceutical Company Inc $0.00, price $0.00, upside -9.1%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Aoxing Pharmaceutical Company Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China.
Show more
Aoxing Pharmaceutical Company, Inc. a specialty pharmaceutical company, engages in research and development, manufacture, and distribution of narcotic, pain-management, and addiction treatment pharmaceutical products primarily in the People's Republic of China. The company's principal products include Zhongtong'an, a capsule of herbal extraction for the indication of oral and dental pain; and Yiqi Qiangshen Granule, an OTC herbal extraction for tonifying qi and empowering body, and promoting blood circulation to remove meridian obstruction, as well as Tilidine hydrochloride, an orally-absorbed synthetic narcotic analgesic tablet used in 50mg or 100mg dosage for relief of acute, moderate to severe pain, and chronic cancer-related pain. Its products under development comprise Oxycodone and Acetaminophen tablets and capsules, which has completed clinical trials for the treatment of acute and chronic pain; Buprenorphine/Naloxone, a sublingual combo tablet that has completed Phase II clinical trials for the treatment of opioid dependence; and Tilidine/Naloxone, a compound capsule which is in Phase II clinical trial to treat acute and chronic pain. The company was formerly known as China Aoxing Pharmaceutical Company, Inc. and changed its name to Aoxing Pharmaceutical Company, Inc. in March 2010. Aoxing Pharmaceutical Company, Inc. was incorporated in 1996 and is based in Foster City, California.
Stock analysis
Aoxing Pharmaceutical Company Inc (AOXG) currently trades at $0.0022, while our model-based Fair Value estimate is $0.0020, so the stock looks roughly fairly valued today (gap 10.0%).
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $0.0100 per share, and 5 of the 5 models we run sit above the $0.0022 price.
Bear case: the Earnings-Based group reads lowest at $0.0100, and 0 of the 5 models stay below the price. Evidence for this calculation is low.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Financial Services sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Aoxing Pharmaceutical Company Inc reported revenue of $32.3M in FY2016 versus $8.1M in FY2012, a compound +41.2%/yr. Reported net income was $55.2K in FY2025.
Key figures
Market cap $1.5M · P/S ratio 0.05 · Net margin −4.9% · Return on equity −7.6% · Return on assets (EBIT) 6.2% · Operating margin 15.4% · Revenue (TTM) $30.1M · Revenue growth (YoY) −13.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (low confidence).
What moves the price
The share trades about 78% below its 52-week high and 100% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Financial Services peers we cover trades at −18% fair-value upside, at −9%, AOXG screens cheaper than that median.
Fair Value models
Bear $0.0020Fair Value $0.0020Bull $0.0020
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.50/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+26.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+44.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+37.2%
Revenue growth 17 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+21.7%
’04
’05
’07
’08
’09
’10
’11
’12
’13
’14
’15
’16
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
Compare Aoxing Pharmaceutical Company Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Shell Companies · 63 stocks
Beats the industry median on 4/8 measures
A mixed picture versus its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−9.1% · Below median
Profitability
Return on assets1.0% · Top 25%
Net margin (TTM)−4.9% · Below median
Operating margin (TTM)15.4% · Top 25%
Growth and dividend
Revenue growth−13.1% · Bottom 25%
Valuation Multiplesvs Shell Companies median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Aoxing Pharmaceutical Company Inc Fair Value". https://www.fairvalue-calculator.com/stock/AOXG
Frequently asked questions
Is Aoxing Pharmaceutical Company Inc (AOXG) overvalued or undervalued?
As of Sep 27, 2026, our model estimates a fair value of $0.0020 versus the last price from Sep 22, 2026 of $0.0022, about −9% upside (fairly valued).
What is the fair value of AOXG?
Our model-based fair value for Aoxing Pharmaceutical Company Inc is $0.0020 (as of Sep 27, 2026), built from audited fundamentals. Last price (from Sep 22, 2026): $0.0022.
What is the quality score of AOXG?
Aoxing Pharmaceutical Company Inc has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Aoxing Pharmaceutical Company Inc (AOXG)?
Our model-based price target is the fair value of $0.0020 (as of Sep 27, 2026) from 7 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the Aoxing Pharmaceutical Company Inc stock forecast for 2026?
Our models put fair value at $0.0020, about −9% upside versus the last price from Sep 22, 2026 of $0.0022 (fairly valued). The calculation is refreshed regularly with new filings.
What is the revenue of Aoxing Pharmaceutical Company Inc (AOXG)?
Aoxing Pharmaceutical Company Inc reported trailing-twelve-month revenue of about $30.1M (latest available figure, as of Sep 27, 2026).
What is the intrinsic value of Aoxing Pharmaceutical Company Inc (AOXG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Aoxing Pharmaceutical Company Inc it is $0.0020 per share (as of Sep 27, 2026), against a price of $0.0022. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is Aoxing Pharmaceutical Company Inc stock overvalued or undervalued in 2026?
As of Sep 27, 2026, AOXG trades above its calculated fair value: price $0.0022, fair value $0.0020, a gap of about −9% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of AOXG?
No. The price is what the market pays today ($0.0022); the fair value is what the company's own numbers justify ($0.0020). For Aoxing Pharmaceutical Company Inc the two are $0.0002 per share apart. That gap is exactly why we show both numbers side by side.
How much is Aoxing Pharmaceutical Company Inc worth?
The market values Aoxing Pharmaceutical Company Inc at about $1.5M (market capitalisation, as of Sep 27, 2026). Per share that is $0.0022; our models calculate a fair value of $0.0020 per share.
How solid is the balance sheet of Aoxing Pharmaceutical Company Inc (AOXG)?
Balance-sheet figures for Aoxing Pharmaceutical Company Inc (as of Sep 27, 2026): return on equity −7.6%. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is AOXG from its 52-week high?
Aoxing Pharmaceutical Company Inc trades at $0.0022, about 78% below its 52-week high of $0.0098 and 100% above the low of $0.0011 (as of Sep 22, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0020 is for.
Which stocks are comparable to Aoxing Pharmaceutical Company Inc?
From the same area (Financial Services) we also value Lionheart III Corp, AA Mission Acquisition Corp, Berto Acquisition Corp, Metals Acquisition Corp, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Aoxing Pharmaceutical Company Inc stock attractive at the current price?
The data as of Sep 27, 2026: price $0.0022, calculated fair value $0.0020 (−9%), Quality Score 32/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of AOXG calculated?
We run Aoxing Pharmaceutical Company Inc through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0020, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Aoxing Pharmaceutical Company Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Aoxing Pharmaceutical Company Inc (AOXG)?
The latest price we hold is from Sep 22, 2026 and stands at $0.0022. Our model-based fair value is $0.0020, about −9% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Aoxing Pharmaceutical Company Inc right now?
The price sits above even our optimistic bull case ($0.0020). The favourable scenario is already priced in. The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual. For a financial, book-value and earnings-based methods matter more than a cash-flow DCF, which fits banks and insurers poorly.
Key figures of Aoxing Pharmaceutical Company Inc
How large is the market capitalisation of Aoxing Pharmaceutical Company Inc (AOXG)?
The market capitalisation of Aoxing Pharmaceutical Company Inc is $1.5M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Aoxing Pharmaceutical Company Inc (AOXG)?
The price-to-sales ratio of Aoxing Pharmaceutical Company Inc is 0.05 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Aoxing Pharmaceutical Company Inc (AOXG)?
The net margin of Aoxing Pharmaceutical Company Inc is −4.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Aoxing Pharmaceutical Company Inc (AOXG)?
The return on equity (ROE) of Aoxing Pharmaceutical Company Inc is −7.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Aoxing Pharmaceutical Company Inc (AOXG)?
On an EBIT basis the return on assets of Aoxing Pharmaceutical Company Inc is 6.2% (avg 3y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Aoxing Pharmaceutical Company Inc (AOXG)?
The operating margin of Aoxing Pharmaceutical Company Inc is 15.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Aoxing Pharmaceutical Company Inc (AOXG)?
Revenue at Aoxing Pharmaceutical Company Inc is growing −13.1% versus a year earlier (3y avg +44.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Aoxing Pharmaceutical Company Inc (AOXG)?
Earnings per share at Aoxing Pharmaceutical Company Inc are growing −78.9% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Aoxing Pharmaceutical Company Inc (AOXG) generate?
The free cash flow of Aoxing Pharmaceutical Company Inc is −$14.8K (fiscal year 2024). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Aoxing Pharmaceutical Company Inc (AOXG) carry?
The net debt of Aoxing Pharmaceutical Company Inc is $18.6M (fiscal year 2016). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Aoxing Pharmaceutical Company Inc in the live analysis
One click puts Aoxing Pharmaceutical Company Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Thin data
Sep 27, 2026